Q3 EPS Forecast for Oruka Therapeutics Reduced by Analyst

by · The Markets Daily

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) – Analysts at HC Wainwright reduced their Q3 2026 earnings estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Thursday, September 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.66) per share for the quarter, down from their previous estimate of ($0.47). HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.54) EPS, Q1 2027 earnings at ($0.67) EPS, Q2 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.72) EPS and FY2027 earnings at ($2.82) EPS.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04).

Other equities research analysts have also issued research reports about the stock. Piper Sandler reissued an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Guggenheim reaffirmed a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. UBS Group boosted their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.00.

Read Our Latest Analysis on ORKA

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $94.31 on Monday. The stock’s 50 day simple moving average is $95.22 and its 200 day simple moving average is $70.70. The firm has a market cap of $6.24 billion, a PE ratio of -46.46 and a beta of -0.34. Oruka Therapeutics has a one year low of $14.66 and a one year high of $115.51.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Arizona State Retirement System raised its position in Oruka Therapeutics by 45.0% in the second quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock valued at $825,000 after purchasing an additional 2,691 shares during the last quarter. Nykredit A S acquired a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $29,000. California State Teachers Retirement System raised its holdings in Oruka Therapeutics by 15,941.3% in the 2nd quarter. California State Teachers Retirement System now owns 3,428,023 shares of the company’s stock valued at $326,245,000 after buying an additional 3,406,653 shares during the last quarter. Braidwell LP acquired a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $26,473,000. Finally, Natural Investments LLC acquired a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $202,000. Institutional investors own 56.44% of the company’s stock.

Insider Activity

In related news, Director Carl Dambkowski sold 12,583 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $70.11, for a total value of $882,194.13. Following the completion of the transaction, the director owned 38,743 shares of the company’s stock, valued at $2,716,271.73. This represents a 24.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $111.84, for a total transaction of $782,880.00. Following the transaction, the insider owned 32,718 shares of the company’s stock, valued at $3,659,181.12. This trade represents a 17.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 158,116 shares of company stock worth $13,523,783. Insiders own 23.49% of the company’s stock.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Recommended Stories